As of 19 Nov 2026, ODAIA has raised $15M across 1 verified round on record, plus 1 round still being checked; latest: US$15m Series C led by Monograph and PHM, announced 17 Nov 2026.
An AI company delivering predictive commercial intelligence for pharma
odaia.aiTorontoAIFounded 2018
20 sources · checked 1 time, last 2d ago
The article reports BetaKit's conflicting estimate of about CA$21 million; the ODAIA release figure of US$15 million wins. The six earlier-round investors are not explicitly named as participants in this round.; not on the page it cites, so not applied: amount
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source states Toronto but does not state a country or state. BDC Capital, MaRS IAF, StandUp Ventures and Panache Ventures are named as current-investor participants in this round despite also appearing in the earlier-round history.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series C | $15M | 2026-11-17 | Monograph, PHM | 11 outlets. #81 in Trending |
20 sources · checked 1 time, last 2d ago [ VERIFIED · CORRECTED ] read against 1 of 20 sources
The article reports BetaKit's conflicting estimate of about CA$21 million; the ODAIA release figure of US$15 million wins. The six earlier-round investors are not explicitly named as participants in this round.; not on the page it cites, so not applied: amount | ||||
ODAIA builds AI-powered commercial intelligence software for pharmaceutical and life-sciences teams, helping them find missed prescription opportunities, prioritize healthcare professionals, and coordinate sales and marketing engagement.
Pharma commercial teams face fragmented data and manual, backward-looking targeting, which can leave prescribing opportunities and patients who need therapies missed. ODAIA turns HCP and patient signals into predictive, explainable actions for field and marketing teams, and its US$15 million Series C is intended to deepen work with existing enterprise customers and bring the platform to more pharma teams.
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $13.8M | 2022-02-10 | Flint Capital | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source
The source states Toronto but does not state a country or state. BDC Capital, MaRS IAF, StandUp Ventures and Panache Ventures are named as current-investor participants in this round despite also appearing in the earlier-round history. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: techcrunch.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ AGENT ]company research by the Firecrawl agent | ||||
Also named as backers in company research: Inovia Capital, Toronto Innovation Acceleration Partners, University of Toronto's UTEST, N49P, Ontario Centres of Excellence (OCE), Amar Varma